Lisata Stock Rallies More Than 30% YTD: Here's Why
Lisata’s Therapeutic Triumphs: A Stock Surge Story A Promising Pipeline In the Biotech Battlefield Investors witnessed a remarkable spectacle in the stock market as Lisata Therapeutics, Inc.’s lead pipeline candidate, certepetide, dazzled with its potential to revolutionize cancer treatment. Previously known as LSTA1, certepetide shines …